Antithrombotic Treatment of Stable Coronary Artery Disease

被引：4

作者：

Li, Yi-Heng ^{[1
]}

Hsieh, I-Chang ^{[2
]}

Ueng, Kwo-Chang ^{[3
]}

Wang, Yu-Chen ^{[4
,5
]}

Cheng, Shu-Meng ^{[6
]}

Wu, Cho-Kai ^{[7
,8
]}

Wu, Chiung-Jen ^{[9
,10
]}

Hsieh, Ming-Hsiung ^{[11
,12
]}

Jen, Hsu-Lung ^{[13
]}

Chang, Chi-Jen ^{[2
]}

Chen, Ying-Hwa ^{[14
,15
]}

机构：

[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Tainan, Taiwan

[2] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Taoyuan, Taiwan

[3] Chung Shan Med Univ Hosp, Taichung, Taiwan

[4] Asia Univ, Asia Univ Hosp, Taichung, Taiwan

[5] China Med Univ, Coll Med & Hosp, Taichung, Taiwan

[6] Triserv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan

[7] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan

[10] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[11] Taipei Med Univ, Taipei, Taiwan

[12] Taipei Wan Fang Hosp, Taipei, Taiwan

[13] Cheng Hsin Gen Hosp, Taipei, Taiwan

[14] Taipei Vet Gen Hosp, Taipei, Taiwan

[15] Natl Yang Ming Chiao Tung Univ, Taipei, Taiwan

来源：

ACTA CARDIOLOGICA SINICA | 2021年 / 37卷 / 06期

关键词：

Antithrombotics; Coronary artery disease; Dual antiplatelet therapy; Dual pathway inhibition; DUAL ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; FOCUSED UPDATE; ESC GUIDELINES; MANAGEMENT; ASPIRIN; RISK; RIVAROXABAN; DETERMINANTS; VALIDATION;

D O I：

10.6515/ACS.202111_37(6).20210513A

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronary artery disease (CAD) is one of the leading causes of death in Taiwan. Despite the use of current guideline-recommended therapies for secondary prevention, the residual risk of recurrent cardiovascular events remains high in CAD, warranting the need for new treatment options. Antithrombotic drugs are one of the most important medical therapies for CAD. In this article, we review the unmet needs of the current antithrombotic agents and summarize the results of clinical trials with dual antiplatelet therapy in stable CAD. We also review data from a recent study demonstrating the benefits of a dual pathway inhibition strategy with antiplatelet and anticoagulant therapy, a new option for CAD treatment. Finally, we propose a treatment algorithm for choosing different antithrombotic regimens for CAD based on current scientific evidence and expert opinions.

引用

页码：574 / 579

页数：6

共 50 条

[21] Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease
Gottsaeter, Anders
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[22] Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
Soini, Erkki
Virtanen, Outi
Vaatainen, Saku
Briere, Jean-Baptiste
Bowrin, Kevin
Millier, Aurelie
ADVANCES IN THERAPY, 2020, 37 (07) : 3348 - 3369
[23] Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials
Bauersachs, Rupert
Wu, Olivia
Briere, Jean-Baptiste
Bowrin, Kevin
Borkowska, Katarzyna
Jakubowska, Anna
Taieb, Vanessa
Toumi, Mondher
Huelsebeck, Maria
CARDIOVASCULAR THERAPEUTICS, 2020, 2020
[24] Colchicine in Stable Coronary Artery Disease
Fiolet, Aernoud T. L.
Nidorf, Stefan M.
Mosterd, Arend
Cornel, Jan H.
CLINICAL THERAPEUTICS, 2019, 41 (01) : 30 - 40
[25] Can a stable coronary artery disease patient be at high ischaemic risk for scheduled non-cardiac surgery?
Lattuca, Benoit
Cayla, Guillaume
Montalescot, Gilles
ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2018, 37 (04) : 313 - 315
[26] Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial
Matsuzawa, Yasushi
Kimura, Kazuo
Yasuda, Satoshi
Kaikita, Koichi
Akao, Masaharu
Ako, Junya
Matoba, Tetsuya
Nakamura, Masato
Miyauchi, Katsumi
Hagiwara, Nobuhisa
Hirayama, Atsushi
Matsui, Kunihiko
Ogawa, Hisao
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (21):
[27] Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease
Neergaard-Petersen, Sos
Larsen, Sanne B.
Grove, Erik L.
Kristensen, Steen D.
Ajjan, Ramzi A.
Hvas, Anne-Mette
THROMBOSIS AND HAEMOSTASIS, 2020, 120 (01) : 75 - 82
[28] Conservative strategy for treatment of stable coronary artery disease
Paulo Cury Rezende
Thiago Luis Scudeler
Leandro Menezes Alves da Costa
Whady Hueb
World Journal of Clinical Cases, 2015, (02) : 163 - 170
[29] Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study
Verma, Sanam
Goodman, Shaun G.
Tan, Mary K.
Daneault, Benoit
Lubelsky, Bruce J.
Mansour, Samer
Lam, Andy S.
Laflamme, David
Tymchak, Wayne J.
Welsh, Robert C.
Rose, Randi C.
Chetty, Rajendra M.
Constance, Christian M.
Cieza, Tomas
Potter, Brian J.
Hartleib, Michael C.
Khan, Razi
Choi, Richard F.
Keeble, William
Dery, Jean-Pierre
Shukla, Dinkar
Chua, Grace L.
Bainey, Kevin R.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021,
[30] Medical Treatment of Patients with Stable Coronary Artery Disease
Perne, A.
Hink, U.
Muenzel, T.
AKTUELLE KARDIOLOGIE, 2014, 3 (05) : 294 - 301

← 1 2 3 4 5 →